The neuroleptic malignant syndrome is a rare, potentially fatal, adverse reaction to neuroleptic drugs characterised by severe rigidity, high temperature and autonomic dysfunction. In the light of the hypothesized pathophysiology of this condition, a rational approach to the management of patients presenting with temperature and rigidity is provided. The aims of this approach are threefold: to reduce the incidence ofthe condition, to be able to recognise it early so as to treat before life-threatening complications arise, and to be able to recognise early those conditions which mimic neuroleptic malignant syndrome, so as not to delay their specific treatment. In the early 1960s Delay described a clinical syndrome caused by neuroleptics, characterised by severe extrapyramidal rigidity, hyperthermia, and unstable respiration, pulse and blood pressure.' The incidence was about 1 % of patients treated with neuroleptics while mortality was thought to be around 40%.2 3This was the neuroleptic malignant syndrome (NMS). Although hundreds of cases of NMS have now been reported in the literature, only a few prospective series are available2 and treatment modalities have not been assessed in prospective randomised controlled trials. However, information available in the literature has led to development of rational approaches to the management of this condition.4
In the early 1960s Delay described a clinical syndrome caused by neuroleptics, characterised by severe extrapyramidal rigidity, hyperthermia, and unstable respiration, pulse and blood pressure.' The incidence was about 1 % of patients treated with neuroleptics while mortality was thought to be around 40%.2 3This was the neuroleptic malignant syndrome (NMS). Although hundreds of cases of NMS have now been reported in the literature, only a few prospective series are available2 and treatment modalities have not been assessed in prospective randomised controlled trials. However, information available in the literature has led to development of rational approaches to the management of this condition. 4 It is possible that a cautious rational use of neuroleptics can actually reduce the incidence of NMS.5 Recognition of the early forms of neuroleptic-induced severe extrapyramidal rigidity (forme fruste NMS), with timely withdrawal of the offending drug can possibly abort the development of full-blown NMS. 4 Furthermore, the early institution of intensive supportive care in full blown cases of NMS, before life-threatening complications set in, can significantly improve outcome. In fact it appears that the mortality of this condition is also on the decrease. 6 The aim of this review is to provide a practical approach to the management of patients presenting with rigidity and temperature. Hypertension and tachycardia can be explained by the hypermetabolic state caused by severe muscle rigidity and hyperthermia. Together with the consequent dehydration and hypoxia, this results in a massive secondary peripheral hyperadrenergic state.9 14 Tachypnoea is the result of decreased chest wall compliance due to severe chest wall muscle rigidity. Tachypnoea of about 40-60 breaths/min, with very small tidal volumes can lead to respiratory failure as inhaled air reaches mostly up to the dead space, with consequent alveolar hypoventilation (box 1).
It is unclear whether the autonomic features are due to the central effects of neuroleptics, or to the peripheral hyperadrenergic state. This author has documented that sudden reversal of rigidity reverses virtually all of the autonomic features.'0 A close parallel between autonomic features and the degree of muscle rigidity has been observed in patients treated with the muscle relaxant dantrolene," so that the second hypothesis seems more likely. The minute-byminute instability of these patients is difficult to explain, although this could reflect subtle changes in muscle rigidity in these short time frames. A chest X-ray to exclude pneumonia, and urinalysis to screen for urinary tract infection are necessary, and blood and urine cultures should be obtained. 4 16 As aspiration pneumonia is a common complication of NMS, the presence of consolidation on chest-X-ray does not exclude NMS.22 A toxicology screen for neuroleptics, anticholinergic and serotinergic drugs is advisable. 2' 24 Severe tachypnoea, with consequent tachypnoeic hypoventilation, may result in respiratory failure. Mechanical ventilation with muscle relaxant use may be necessary in a minority of cases. It has now been shown that malignant hyperthermia is a totally separate condition from NMS and for this reason cross-reactivity between neuroleptics and muscle relaxants is unlikely to occur. '5 Once the patient's condition is under control, being adequately monitored, and the diagnosis of NMS is a confident one, specific treatment can be given. Dopaminergic therapy with agents such as L-dopa, bromocriptine and amantadine by nasogastric tube are thought to speed up the reversal of this massive central dopaminergic blockade.2"" A progressive increase in dose, from 7.5 mg to 60 mg of bromocriptine daily, is widely used. Secondly, where muscle rigidity is severe, and body temperature difficult to control, dantrolene, a muscle relaxant which prevents calcium release in the sarcolemmal membrane can be used. The reduction in muscle rigidity is achieved by doses between 1-2 mg/kg and 10 mg/kg in four divided doses. Dantrolene decreases heat production and improves respiration by improving chest compliance, thus attenuating the peripheral hyperadrenergic state.'0 17 However, because no prospective randomised controlled trial has been carried out to date, whether the duration of NMS is shortened or not by this drug remains unestablished.29"
A number of cases of apparent NMS have occurred in the absence of neuroleptic therapy, particularly in the context of catatonia progressing into malignant catatonia.32 Electroconvulsive therapy (ECT) with full anaesthesia and muscle relaxation has been used with good results."3 The role of ECT in NMS with neuroleptic use is controversial.'4 It should be reserved for cases of NMS that fail to respond to supportive and pharmacological therapy, and for psychiatric treatment of patients having recovered from NMS. 
